Dimethyl fumarate controlled-release - Forward Pharma

Drug Profile

Dimethyl fumarate controlled-release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • Preclinical Multiple sclerosis

Most Recent Events

  • 29 Jan 2018 European Patent Office revokes EP 2 801 355 patent following the oral hearing in the opposition proceedings
  • 29 Nov 2017 Forward Pharma files further written submissions in the European Opposition Proceeding for the EP 2 801 355 patent with the Opposition Division of the European Patent Office
  • 31 May 2017 Forward Pharma challenges the decision by the PTAB in the patent interference lawsuit filed by Forward Pharma related to oral administration of dimethyl fumarate 480mg for Multiple sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top